H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best biotech stocks to buy. On September 16, H.C. Wainwright reaffirmed its $50 price target and Buy rating for Summit Therapeutics Inc. (NASDAQ:SMMT). The firm emphasized that Summit’s ivonescimab, a PD-1 x VEGF bispecific antibody, has accomplished clinical milestones that are unprecedented in PD-1 medicines, including improved results in the HARMONi-2 trial conducted in China. H.C. Wainwright believes that investors now have a “highly risk-mitigat ...